Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEHA study: Amivantamab + Lazertinib vs Afatinib in uncommon / compound EGFR-mutated NSCLC
jRCTs031250560Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Amivantamab + Lazertinib with Afatinib standard-of-care (2 arms). Primary endpoint: Progression-free survival (BICR). Started Feb 2026; status: recruiting.
02
Drugs
amivantamablazertinibafatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031250560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250560.